204 related articles for article (PubMed ID: 16413390)
1. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Bamberger M; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2006 Jan; 34(1):44-53. PubMed ID: 16413390
[TBL] [Abstract][Full Text] [Related]
2. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Moosmann A; Kofler DM; Hallek M; Wendtner CM
Blood; 2005 Feb; 105(4):1566-73. PubMed ID: 15471955
[TBL] [Abstract][Full Text] [Related]
3. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes.
Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2007 Jun; 35(6):920-30. PubMed ID: 17533046
[TBL] [Abstract][Full Text] [Related]
4. Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells.
Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2006 Jul; 34(7):860-9. PubMed ID: 16797413
[TBL] [Abstract][Full Text] [Related]
5. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
6. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.
Voss RH; Kuball J; Engel R; Guillaume P; Romero P; Huber C; Theobald M
Immunol Res; 2006; 34(1):67-87. PubMed ID: 16720899
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
[TBL] [Abstract][Full Text] [Related]
8. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
9. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
Giannopoulos K; Dmoszynska A; Kowal M; Rolinski J; Gostick E; Price DA; Greiner J; Rojewski M; Stilgenbauer S; Döhner H; Schmitt M
Leukemia; 2010 Apr; 24(4):798-805. PubMed ID: 20220777
[TBL] [Abstract][Full Text] [Related]
10. CD8 T-cell recognition of human 5T4 oncofetal antigen.
Smyth LJ; Elkord E; Taher TE; Jiang HR; Burt DJ; Clayton A; van Veelen PA; de Ru A; Ossendorp F; Melief CJ; Drijfhout JW; Dermime S; Hawkins RE; Stern PL
Int J Cancer; 2006 Oct; 119(7):1638-47. PubMed ID: 16646078
[TBL] [Abstract][Full Text] [Related]
11. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
Grube M; Rezvani K; Wiestner A; Fujiwara H; Sconocchia G; Melenhorst JJ; Hensel N; Marti GE; Kwak LW; Wilson W; Barrett JA
Clin Cancer Res; 2004 Feb; 10(3):1047-56. PubMed ID: 14871984
[TBL] [Abstract][Full Text] [Related]
12. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.
Britten CM; Meyer RG; Kreer T; Drexler I; Wölfel T; Herr W
J Immunol Methods; 2002 Jan; 259(1-2):95-110. PubMed ID: 11730845
[TBL] [Abstract][Full Text] [Related]
13. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells.
Mayr C; Kofler DM; Büning H; Bund D; Hallek M; Wendtner CM
Blood; 2005 Nov; 106(9):3223-6. PubMed ID: 16014560
[TBL] [Abstract][Full Text] [Related]
14. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
[TBL] [Abstract][Full Text] [Related]
15. A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia.
Kronenberger K; Nössner E; Frankenberger B; Wahl U; Dreyling M; Hallek M; Mocikat R
J Immunother; 2008 Oct; 31(8):723-30. PubMed ID: 18779747
[TBL] [Abstract][Full Text] [Related]
16. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
Weng J; Rawal S; Chu F; Park HJ; Sharma R; Delgado DA; Fayad L; Fanale M; Romaguera J; Luong A; Kwak LW; Neelapu SS
Blood; 2012 Aug; 120(8):1613-23. PubMed ID: 22645177
[TBL] [Abstract][Full Text] [Related]
17. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
[TBL] [Abstract][Full Text] [Related]
18. CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients.
Vikman S; Giandomenico V; Sommaggio R; Oberg K; Essand M; Tötterman TH
Cancer Immunol Immunother; 2008 Mar; 57(3):399-409. PubMed ID: 17717663
[TBL] [Abstract][Full Text] [Related]
19. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
[TBL] [Abstract][Full Text] [Related]
20. The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells.
Kondo E; Maecker B; Draube A; Klein-Gonzalez N; Shimabukuro-Vornhagen A; Schultze JL; von Bergwelt-Baildon MS
Int J Cancer; 2009 Nov; 125(10):2474-8. PubMed ID: 19681121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
